BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapies for challenging conditions. This includes cancers that are immune-evasive, drug-resistant, or metastatic, as well as various respiratory diseases. Its leading drug candidate, Bemcentinib, is an orally available, small molecule AXL inhibitor that has progressed to Phase II clinical development. This involves studies across several significant cancer indications and for COVID-19. Specifically, its Phase II trials are focused on treating non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Another promising compound in its pipeline is tilvestamab, an anti-AXL antibody currently undergoing Phase Ib clinical evaluation. The company maintains a collaborative agreement with Merck & Co. concerning its clinical trial initiatives. Founded in 2007, BerGenBio ASA is headquartered in Bergen, Norway.